Ethanol
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Ethanol: From an Unspecified Original Indication to Migraine Disorder
One-Sentence Summary
Ethanol appears in the India market as a component of a solvent product supplied with docetaxel injection, and no approved indication text is recorded for it. The TxGNN model predicts it may be effective for migraine disorder, but there are no clinical trials and the retrieved literature suggests ethanol is more likely a migraine trigger than a treatment. This prediction rests on a model score alone and is not supported by actual studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated (the single registration has no approved indication text) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9929 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. The only registered ethanol product in India is a solvent for docetaxel injection, so its role there is as a pharmaceutical excipient and not as a treatment for a specific disease. No original indication is recorded that could be linked to migraine.
The literature points in the opposite direction from the model’s prediction. Ethanol is a recognised migraine trigger. A preclinical study in mice (PMID 37101198) shows that ethanol is metabolised to acetaldehyde, which acts through CGRP receptors and TRPA1 in Schwann cells to cause periorbital mechanical allodynia. This is a pain-promoting pathway. The other retrieved papers on migraine pathophysiology (KATP channels, spreading depression) and genetic susceptibility (ADH2, GABA receptors, NOS3) describe how migraine arises and do not show a therapeutic benefit from ethanol.
The high TxGNN score (0.9929) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The second-ranked prediction, migraine with brainstem aura (score 0.9914), has the same limitation. It has no trials and no studies of ethanol as a treatment. One hit (PMID 30177906) concerns palmitoylethanolamide, a different compound, and appears to be a keyword match on “ethanol” only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the publications below tests ethanol as a migraine treatment. Papers on unrelated drugs are excluded.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36373782 | 2022 | Review | Headache | Reviews the complex relationship between alcohol and migraine. |
| 37101198 | 2023 | Preclinical | J Biomed Sci | Acetaldehyde, an ethanol metabolite, acts via CGRP receptor and TRPA1 to cause pain-like behaviour in mice, a pro-migraine mechanism. |
| 19486361 | 2010 | Genetic association | Headache | Examines the alcohol dehydrogenase 2 genotype and migraine risk. |
| 40785517 | 2025 | Preclinical | Cephalalgia | Opening of KATP channels activates meningeal nociceptors, which has implications for migraine origin. |
| 31231207 | 2019 | Review | Front Aging Neurosci | Reviews the spreading depression model in brain ageing. |
| 35063053 | 2022 | Cohort | Aerosp Med Hum Perform | Migraine history and outcomes in military pilots; not specific to ethanol. |
| 29299688 | 2018 | Genetic association | J Neural Transm | GABA receptor gene variants and migraine risk. |
| 31792366 | 2020 | Genetic association | Pharmacogenomics J | NOS3 variant and migraine risk. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 206079 | Solvent for Docetaxel 120 mg Injection (Alkem Laboratories Ltd) | Vial of 9 ml injection | Not stated |
Safety Considerations
Drug Interactions: The data compiled for this report list 471 interacting drugs. Most are moderate, and some are minor. The only major interaction in the displayed subset is with eluxadoline. Moderate interactions are shown with:
- Antidiabetic agents (acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, dapagliflozin, empagliflozin, albiglutide, dulaglutide)
- Anticholinergic agents (atropine, clidinium, dicyclomine)
- Others (acetylsalicylic acid, bupropion, dronabinol)
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials and no supportive studies. The available mechanistic evidence suggests ethanol promotes migraine and does not treat it. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India Pharma source, which are currently missing and block safety screening
- Detailed mechanism of action data from DrugBank
- Any original indication for ethanol as a drug, beyond its use as a solvent in the docetaxel product
- Direct clinical evidence that ethanol relieves migraine, since none currently exists
- Review of whether the TxGNN score reflects similarities the model learned between related diseases and not therapeutic evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.